Author:
Wegman Pia,Vainikka Linda,Stål Olle,Nordenskjöld Bo,Skoog Lambert,Rutqvist Lars-Erik,Wingren Sten
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Early Breast Cancer Trialist's Collaborative Group (EBCTCG): Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 352: 1451-1467.
2. Fuqua SAW, Wiltschke C, Zhang QX, Borg Å, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred C: Hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res. 2000, 60: 4026-4029.
3. McClelland RA, Barrow D, Madden T-A, Dutkowski CM, Pamment J, Knowlden JM, Gee JMW, Nicholson RI: Enhanced epidermal growth factor receptor signalling in MCF-7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex)*. Endocrinology. 2001, 142: 2776-2788. 10.1210/en.142.7.2776.
4. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 Cells. Endocrinology. 2003, 144: 1032-1044. 10.1210/en.2002-220620.
5. Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev. 2002, 2: 101-112. 10.1038/nrc721.
Cited by
191 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献